Michael addition drugs and cancer

Area of Science:

• Medicinal Chemistry
• Organic Chemistry
• Oncology

Background:

• Alkylating agents were early anticancer drugs modifying proteins and nucleic acids.
• Michael addition reactions, involving nucleophilic attack on α,β-unsaturated carbonyl compounds, are explored for covalent inhibitors.
• Natural products with Michael addition properties exhibit antioxidant, anti-inflammatory, and anticancer activities by modulating cellular processes.

Purpose of the Study:

• To review the mechanisms, applications, and therapeutic potential of Michael addition drugs in oncology.
• To highlight advances in medicinal chemistry for improved selectivity and efficacy of covalent inhibitors.
• To discuss challenges such as off-target effects, toxicity, and drug resistance associated with these drugs.

Main Methods:

• Literature review of Michael addition chemistry in drug design.
• Analysis of FDA-approved drugs utilizing Michael addition for irreversible inhibition.
• Examination of natural products and emerging covalent inhibitors leveraging Michael addition.

Main Results:

• Michael addition chemistry is employed in several FDA-approved drugs (e.g., proteostatic, EGFR, Ras inhibitors) for irreversible target inhibition.
• Natural products with Michael addition properties modulate redox signaling, enzyme catalysis, and stress response pathways.
• Medicinal chemistry advances have led to improved selectivity and therapeutic efficacy, with ongoing efforts for clinical translation.

Conclusions:

• Michael addition drugs offer significant potential in cancer treatment through targeted covalent inhibition.
• Overcoming challenges like toxicity and drug resistance is crucial for advancing these therapies.
• Emerging covalent inhibitors utilizing Michael addition represent a promising frontier in oncology drug development.